Biohaven completed a registered offering of $200 million of common shares, which included the full exercise of the underwriters’ option to purchase additional common shares.
J.P. Morgan, Goldman Sachs, Leerink Partners, TD Cowen and Cantor acted as the bookrunning managers of the offering.
Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience and oncology.
The S&C team included Bob Downes, John Karol, Somin Park and Taylor Scott. Davis Wang, John Jo and Eli Dubin advised on tax matters.
This is S&C’s fourth registered equity deal and the latest transaction in the Firm’s longstanding relationship with Biohaven, including its spin-off in connection with the $11.6 billion acquisition of Biohaven Pharma by Pfizer in 2022.